HCC Biomarkers - Information for Health Care Providers
The HCC Biomarker tests AFP-L3 and DCP are in vitro diagnostic blood tests for the risk assessment of developing Hepatocellular Carcinoma (HCC). Both tests are used in conjunction with imaging studies, clinical assessment and other laboratory findings and are CE-certified. They are run on the µTASWakoTM i30 device.
HCC surveillance improves patient outcome
In Europe, about 70% of all cases of Hepatocellular Carcinoma (HCC) are diagnosed at an advanced stage and curative treatments are only available for a minority of patients. Therefore, optimal surveillance of at-risk patients is crucial for the early detection of HCC.
The current guideline from the European Association for the Study of the Liver (EASL) and the European Organization for Research and Treatment of Cancer (EORTC) recommends that patients with a high risk of liver cancer should be screened at 6-month intervals using abdominal ultrasound1. However, ultrasound is highly operator dependent and its performance is limited when used on patients who are obese or have a severe background liver cirrhosis.
Several studies have shown that AFP-L3 and DCP are complementary markers for liver cancer. HCCs are biologically not homogeneous. Some express normal levels of AFP, but high levels of AFP-L3 or DCP and vice versa. The combined use of these three markers provides higher clinical sensitivity and is effective for the early recognition of HCC2/3.
The determination of the markers allows the serological detection of tumors in early stages even if the AFP shows negative results. In a broad investigation of 270 HCC patients who all had a serum AFP of less than 20 ng/ml, the combined use of the biomarkers detected 49% of all patients with tumors with the size of less than 2 centimeteres.4
Thus, adding AFP-L3 and DCP to HCC surveillance can increase the chances of detecting early HCC and therefore, should be incorporated into regular surveillance practices. The HCC management guideline of the Japan Society of Hepatology includes all three serum biomarkers for surveillance5. A 2010 survey report on surveillance efficacy in Japan concluded that out of all patients with HCC, 33.5% had tumors of 2 centimetres or less and more than 62% had undergone surgery or local ablation therapy which represent treatment options that are only available for early stage HCC6.
The GALAD score improves diagnostic performance
Investigators around Prof. Johnson from the UK established an algorithm, in which gender, age, AFP-L3, AFP and DCP are calculated. This so-called GALAD score can detect early stages of HCC at a sensitivity of at least 75% and a specificity of 89%7.
Recently, the GALAD model was validated in an international setting by analyzing nearly 7,000 datasets from the UK, Germany, Japan and Hong Kong. AUROC analysis in all cohorts showed better values for GALAD compared to individual or combined markers. The model performance did not vary between the etiologies HBV, HCV and “others”. It even performed well in small and early HCC with AUC values of at least 0.85 and could successfully discriminate between HCC and other hepatobiliary cancers8.
The BALAD-2 score enables a prognosis assessment
The British research group established another model called BALAD-2. It includes markers of liver disease severity (bilirubin and albumin) and markers of tumor biology (AFP, AFP-L3 and DCP). BALAD-2 analyses assign patients into four distinct prognostic groups from relatively best to worst survival9.
Prof. A. Vogel, Clinic of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Germany, explains in an interview how the GALAD and BALAD-2 models can be used in the surveillance and prognosis of patients with hepatocellular carcinoma (HCC). To watch this interview, please click here.
- AFP-L3 and DCP tests are CE-certified
- Combined use of AFP, AFP-L3 and DCP increases the sensitivity of HCC detection
- Markers increase the chance of detecting HCC early of patients at risk
- GALAD score specifically detects early HCC at high sensitivity nearly irrespective of etiology
1EASL-EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol 2012 (56): 908-943
2Ertle J. et al., A combination of α-fetoprotein and des-γ-carboxy prothrombin is superior in detection of hepatocellular carcinoma. Digestion 2013;87(2):121-31
3 Ohmura et al., Annual Meeting of Japanese Society of Laboratory Medicine, 2009
4Toyoda H. et al., Clinical utility of highly sensitive Lens culinaris agglutinin-reactive alpha-fetoprotein in hepatocellular carcinoma patients with alpha-fetoprotein <20 ng/mL. Cancer Sci. 2011;102(5):1025-31
5Makuuchi M. et al., Development of evidence-based clinical guidelines for the diagnosis and treatment of hepatocellular carcinoma in Japan. Hepatol Res. 2008;38:37-51
6Ikai I. et al., Report of the 18th follow-up survey of primary liver cancer in Japan. Hepatol Res. 2010;40:1043-59
7Johnson P. et al., The detection of hepatocellular carcinoma using a prospectively developed and validated model based on serological biomarkers. Cancer Epidemiol Biomarkers Prev. 2014 Jan;23(1):144-53
8Berhane S. et al., Role of the GALAD and BALAD-2 Serologic Models in Diagnosis of Hepatocellular Carcinoma and Prediction of Survival in Patients. Clin Gastroenterol Hepatol. 2016 Jan 13; Epub ahead of print
9Fox R et al., Biomarker-based Prognosis in Hepatocellular Carcinoma: Validation and Extension of the BALAD model, British Journal of Cancer, April 2014, 110 (8): 2090-2098